US Stock MarketDetailed Quotes

RGNX Regenxbio

Watchlist
  • 6.720
  • +0.170+2.60%
Close Mar 14 16:00 ET
  • 6.720
  • 0.0000.00%
Post 19:12 ET
336.58MMarket Cap-1.46P/E (TTM)

About Regenxbio Company

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Company Profile

SymbolRGNX
Company NameRegenxbio
Listing DateSep 17, 2015
Issue Price22.00
Founded2008
CEOMr. Curran Simpson
MarketNASDAQ
Employees344
Fiscal Year Ends12-31
Address9804 Medical Center Drive
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-552-8181
Websitehttp://www.regenxbio.com

Company Executives

  • Name
  • Position
  • Salary
  • Curran Simpson
  • Director, President and Chief Executive Officer
  • 2.95M
  • Dr. Olivier Danos, PhD
  • Executive Vice President and Chief Scientific Officer
  • 2.99M
  • Patrick J. Christmas
  • Executive Vice President and Chief Legal Officer
  • --
  • Stephen Pakola, M.D.
  • Executive Vice President and Chief Medical Officer
  • 3.31M
  • Mitchell Chan
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • --
  • Kenneth T. Mills
  • Chairman of the Board
  • 5.92M
  • Allan M. Fox
  • Director
  • 354.98K
  • Dr. Jean Bennett, M.D.,Pd.D
  • Independent Director
  • 324.98K
  • Dr. Alexandra Glucksmann, PhD
  • Independent Director
  • 327.48K
  • Daniel Tasse
  • Lead Independent Director
  • 334.98K
  • Dr. David C. Stump,M.D.
  • Independent Director
  • 339.98K
  • Jennifer Zachary
  • Independent Director
  • 329.98K
  • Dr. Argeris N. Karabelas, PhD
  • Independent Director
  • 352.48K
  • George V. Migausky
  • Independent Director
  • 339.98K

Trending Stocks

U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks

Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Bit Origin
BTOG
0.3100
TeraWulf
WULF
3.260
BTCS Inc
BTCS
1.870
4
MARA Holdings
MARA
13.180
5
Hut 8
HUT
12.620
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More
FOMC Press Conference, January 29, 2025
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.